A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1

Lilly

Status and phase: Not yet enrolling; Phase 3

Conditions: Hypertension; Overweight or Obesity

Treatments: Drug: Placebo; Drug: Orforglipron

Study type: Interventional

Funder types: Industry

Identifiers

NCT06948435

J2A-MC-GZPL (Other Identifier)

J2A-MC-GZL1 (Other Identifier)

27359

Details and patient eligibility

About

GZL1 is an independent study conducted under the GZPL master protocol. GZL1 will evaluate the efficacy and safety of orforglipron for treatment of hypertension in participants with obesity or overweight.

Enrollment: 487 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• refer to the GZPL master protocol for screening eligibility.

Exclusion criteria

• refer to the GZPL master protocol for screening eligibility.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

487 participants in 2 patient groups, including a placebo group

Orforglipron

Experimental group

Description:

Participants will receive orforglipron orally.

Treatment:

Drug: Orforglipron

Placebo

Placebo Comparator group

Description:

Administered placebo.

Treatment:

Drug: Placebo